{"title":"治疗复发难治多发性骨髓瘤的新疗法即将问世。","authors":"Nadine Abdallah MD, Shaji K. Kumar MD","doi":"10.1016/j.hoc.2023.12.013","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":55060,"journal":{"name":"Hematology-Oncology Clinics of North America","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"New Therapies on the Horizon for Relapsed Refractory Multiple Myeloma\",\"authors\":\"Nadine Abdallah MD, Shaji K. Kumar MD\",\"doi\":\"10.1016/j.hoc.2023.12.013\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":55060,\"journal\":{\"name\":\"Hematology-Oncology Clinics of North America\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2024-01-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hematology-Oncology Clinics of North America\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0889858823001806\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematology-Oncology Clinics of North America","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0889858823001806","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
尽管治疗方法有所改进,但大多数多发性骨髓瘤(MM)患者仍会复发。一些新型药物在早期临床试验中显示出了活性和耐受性。Venetoclax 是一种 B 细胞淋巴瘤 2(Bcl-2)抑制剂,对有 t(11;14)和/或 Bcl-2 表达的患者有活性。Iberdomide和mezigdomide是脑龙E3连接酶调节剂,与来那度胺和泊马度胺相比,具有更高的效力、免疫调节和抗增生活性。它们在接受大量预处理的患者中显示出良好的活性。Modakafusp alfa 是一种免疫细胞因子,可将干扰素靶向 CD38+ 细胞。在 1 期治疗中,它已在复发/难治性 MM 中显示出单药活性。
期刊介绍:
Hematology/Oncology Clinics updates you on the latest trends in patient management, keeps you up to date on the newest advances, and provides a sound basis for choosing treatment options. Under the direction of an experienced guest editor, each issue focuses on a single topic in hematology and oncology, including hemostasis and thrombosis, molecular and cellular basis of hematology, coagulation disorders, and cancers—bone, gastrointestinal, head and neck, lymphomas, neuroendocrine, breast, renal cell, melanoma, and more.